NL990006I2 - N-gesubstitueerde heterocyclische derivaten, de bereiding hiervan, farmaceutische preparaten die deze bevatten. - Google Patents

N-gesubstitueerde heterocyclische derivaten, de bereiding hiervan, farmaceutische preparaten die deze bevatten.

Info

Publication number: NL990006I2
Authority: NL; Netherlands
Prior art keywords: alkyl; phenyl; carbonyl; alkoxy; halogen
Prior art date: 1990-03-20

Application number

NL990006C

Other languages

English (en)

Other versions

NL990006I1 (nl

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-20

Filing date

1999-03-05

Publication date

1999-10-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26227935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL990006(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-03-20 Priority claimed from FR9003563A external-priority patent/FR2659967B1/fr

1990-08-08 Priority claimed from FR9010144A external-priority patent/FR2665702B1/fr

1999-03-05 Application filed by Sanofi Sa filed Critical Sanofi Sa

1999-05-03 Publication of NL990006I1 publication Critical patent/NL990006I1/nl

1999-10-01 Publication of NL990006I2 publication Critical patent/NL990006I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Hospice & Palliative Care (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Paints Or Removers (AREA)
Organic Insulating Materials (AREA)
Cephalosporin Compounds (AREA)

NL990006C 1990-03-20 1999-03-05 N-gesubstitueerde heterocyclische derivaten, de bereiding hiervan, farmaceutische preparaten die deze bevatten. NL990006I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9003563A FR2659967B1 (fr)	1990-03-20	1990-03-20	Derives d'imidazolinone n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
FR9010144A FR2665702B1 (fr)	1990-08-08	1990-08-08	Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant.

Publications (2)

Publication Number	Publication Date
NL990006I1 NL990006I1 (nl)	1999-05-03
NL990006I2 true NL990006I2 (nl)	1999-10-01

Family

ID=26227935

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NL980039C NL980039I2 (nl)	1990-03-20	1998-12-02	N-gesubstitueerde heterocyclische derivaten, de bereiding hiervan, farmaceutische preparaten die deze bevatten.
NL990006C NL990006I2 (nl)	1990-03-20	1999-03-05	N-gesubstitueerde heterocyclische derivaten, de bereiding hiervan, farmaceutische preparaten die deze bevatten.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NL980039C NL980039I2 (nl)	1990-03-20	1998-12-02	N-gesubstitueerde heterocyclische derivaten, de bereiding hiervan, farmaceutische preparaten die deze bevatten.

Country Status (30)

Country	Link
EP (1)	EP0454511B1 (nl)
JP (2)	JP2868313B2 (nl)
KR (1)	KR0175310B1 (nl)
AT (1)	ATE167475T1 (nl)
AU (1)	AU641005B2 (nl)
CA (1)	CA2057913C (nl)
CZ (2)	CZ287064B6 (nl)
DE (2)	DE19975029I2 (nl)
DK (1)	DK0454511T3 (nl)
ES (1)	ES2119764T3 (nl)
FI (1)	FI103407B1 (nl)
HK (1)	HK1008918A1 (nl)
HU (3)	HU221188B1 (nl)
IE (1)	IE910913A1 (nl)
IL (3)	IL110820A (nl)
LU (2)	LU90279I2 (nl)
LV (1)	LV10439B (nl)
MX (1)	MX9203586A (nl)
MY (1)	MY115638A (nl)
NL (2)	NL980039I2 (nl)
NO (3)	NO301977B1 (nl)
NZ (1)	NZ237476A (nl)
PL (3)	PL165945B1 (nl)
PT (1)	PT97078B (nl)
RU (1)	RU2099331C1 (nl)
SG (1)	SG49053A1 (nl)
SK (2)	SK283197B6 (nl)
TW (1)	TW201738B (nl)
UA (1)	UA42669A (nl)
WO (1)	WO1991014679A1 (nl)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE122007000050I1 (de) *	1990-02-19	2007-11-08	Novartis Ag	Acylverbindungen
CA2053148A1 (en) *	1990-10-16	1992-04-17	Karnail Atwal	Dihydropyrimidine derivatives
DE69131021T2 (de) *	1990-12-14	1999-08-12	Smithkline Beecham Corp., Philadelphia, Pa. 19101	Angiotensin-ii-rezeptor blockierende zusammensetzungen
FR2673427B1 (fr) *	1991-03-01	1993-06-18	Sanofi Elf	Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
IL101860A0 (en) *	1991-05-31	1992-12-30	Ici Plc	Heterocyclic derivatives
IL102183A (en) *	1991-06-27	1999-11-30	Takeda Chemical Industries Ltd	The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
CA2115990A1 (en) *	1991-08-19	1993-03-04	George Albert Boswell	Angiotensin ii receptor blocking imidazolinone derivatives
CZ36294A3 (en) *	1991-08-19	1994-07-13	Du Pont	Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
US5182288A (en) *	1991-11-13	1993-01-26	Ortho Pharmaceutical Corporation	Substituted n-biphenylyl lactams
FR2685328B1 (fr) *	1991-12-20	1995-12-01	Rhone Poulenc Agrochimie	Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
ZA931063B (en) *	1992-02-17	1993-09-23	Ciba Geigy	Treatment of glaucoma.
US5326776A (en) *	1992-03-02	1994-07-05	Abbott Laboratories	Angiotensin II receptor antagonists
FR2688781B1 (fr) *	1992-03-23	1994-07-01	Sanofi Elf	Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
EP0577025A3 (de) *	1992-07-01	1998-02-04	Hoechst Aktiengesellschaft	Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
GB9218449D0 (en)	1992-08-29	1992-10-14	Boots Co Plc	Therapeutic agents
DE69330593T2 (de) *	1992-12-22	2002-06-27	Takeda Chemical Industries, Ltd.	Heterocyclische Verbindungen mit Angiotensin-II-antagonistischer Wirkung und ihre Anwendung
FR2711367B1 (fr) *	1993-10-19	1995-12-01	Roussel Uclaf	Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
US5338740A (en) *	1993-07-13	1994-08-16	Pfizer Inc.	Angiotensin II receptor antagonists
US5411641A (en) *	1993-11-22	1995-05-02	E. I. Du Pont De Nemours And Company	Electrochemical conversion of anhydrous hydrogen halide to halogen gas using a cation-transporting membrane
US5994348A (en)	1995-06-07	1999-11-30	Sanofi	Pharmaceutical compositions containing irbesartan
TW442301B (en) *	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
MY119312A (en) *	1995-10-06	2005-05-31	Novartis Ag	At 1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
CA2196263C (en) *	1996-02-09	2004-10-26	Barry Jackson	Process for the preparation of 4-oxoimidazolinium salts
ES2189940T3 (es)	1996-02-29	2003-07-16	Novartis Ag	Antagonista de receptor at1 para la estimulacion de la apoptosis.
JP2000506861A (ja) *	1996-03-14	2000-06-06	ワーナー―ランバート・コンパニー	医薬としての新規な置換環状アミノ酸
HU218681B (hu)	1997-07-25	2000-10-30	Sanofi-Synthelabo	Eljárás 1,3-diaza-spiro(4,4)non-1-én-4-on-származékok előállitására és 1-ciano-1-(acil-amino)-ciklopentán intermedierek
US6162922A (en) *	1998-01-30	2000-12-19	Bristol-Myers Squibb Co.	Method for preparing N-substituted heterocyclic derivatives using a phase-transfer catalyst
AU757290B2 (en) *	1998-03-25	2003-02-13	Bristol-Myers Squibb Company	Imidazolone anorectic agents: II. phenyl derivatives
FR2780403B3 (fr) *	1998-06-24	2000-07-21	Sanofi Sa	Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
US6638937B2 (en)	1998-07-06	2003-10-28	Bristol-Myers Squibb Co.	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CN1636561A (zh)	1998-12-23	2005-07-13	诺瓦提斯公司	At－1受体拮抗剂在治疗与at－1受体增加有关的疾病中的应用
US6211217B1 (en)	1999-03-16	2001-04-03	Novartis Ag	Method for reducing pericardial fibrosis and adhesion formation
SE9903028D0 (sv)	1999-08-27	1999-08-27	Astra Ab	New use
PE20020617A1 (es)	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US8168616B1 (en)	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
FR2831446B1 (fr)	2001-10-26	2004-03-05	Sanofi Synthelabo	Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
US7232828B2 (en)	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10335027A1 (de)	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en)	2003-07-15	2003-08-20	Novartis Ag	Process for the manufacture of organic compounds
US7829552B2 (en)	2003-11-19	2010-11-09	Metabasis Therapeutics, Inc.	Phosphorus-containing thyromimetics
GB0327839D0 (en)	2003-12-01	2003-12-31	Novartis Ag	Organic compounds
GB0402262D0 (en)	2004-02-02	2004-03-10	Novartis Ag	Process for the manufacture of organic compounds
NZ549535A (en)	2004-03-17	2010-11-26	Novartis Ag	Use of aliskiren for treating renal and other disorders
ES2282062T1 (es)	2004-06-04	2007-10-16	Teva Pharmaceutical Industries Ltd.	Composicion farmaceutica que contiene irbesartan.
WO2005122699A2 (en) *	2004-06-16	2005-12-29	Matrix Laboratories Ltd	An improved process for the preparation of n-substituted hetero cyclic derivatives
SI21849A (sl)	2004-07-29	2006-02-28	Krka, Tovarna Zdravil, D.D., Novo Mesto	Priprava hidrokloridnih soli tetrazolskega derivata
TWI346108B (en)	2004-08-23	2011-08-01	Bristol Myers Squibb Co	A method for preparing irbesartan and intermediates thereof
JP2008515903A (ja)	2004-10-08	2008-05-15	ノバルティスアクチエンゲゼルシャフト	拡張機能障害または拡張期心不全の予防または処置のためのレニン阻害剤の使用
GB2419592A (en)	2004-10-26	2006-05-03	Cipla Ltd	Process for the preparation of irbesartan hydrochloride
WO2006046593A1 (ja)	2004-10-27	2006-05-04	Daiichi Sankyo Company, Limited	２以上の置換基を有するベンゼン化合物
FR2886642B1 (fr) *	2005-06-06	2008-05-30	Sanofi Aventis Sa	Sels alcalino-terreux d'irbesartan et leur preparation
EP1749828A1 (en)	2005-08-04	2007-02-07	Farmaprojects S.L.	Process for preparing an angiotensin II receptor antagonist
CA2604404A1 (en)	2005-10-28	2007-05-03	Alembic Limited	An improved process for preparation of irbesartan
ES2340701T3 (es)	2006-01-09	2010-06-08	Krka, D.D., Novo Mesto	Composicion farmaceutica solida que comprende irbesartan.
EP1908469A1 (en)	2006-10-06	2008-04-09	Boehringer Ingelheim Vetmedica Gmbh	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1918288A1 (en)	2006-11-02	2008-05-07	Cadila Pharmaceuticals Limited	A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension
MX2009009234A (es)	2007-03-01	2009-12-01	Probiodrug Ag	Uso nuevo de inhibidores de ciclasa de glutaminilo.
WO2008128985A1 (en)	2007-04-18	2008-10-30	Probiodrug Ag	Thiourea derivatives as glutaminyl cyclase inhibitors
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en)	2008-06-04	2010-05-13	Synergy Pharmaceuticals, Inc.	Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US7879802B2 (en)	2007-06-04	2011-02-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PE20090818A1 (es)	2007-10-16	2009-07-24	Novartis Ag	Compuestos heterociclicos como moduladores de los receptores de npy y2
EP2065035B1 (en)	2007-11-28	2010-07-21	Laboratorios Lesvi, S.L.	Pharmaceutical formulations containing irbesartan
WO2009149734A1 (en) *	2008-06-13	2009-12-17	Ratiopharm Gmbh	Process for the preparation of irbesartan and intermediate products
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
EP2194050A1 (en)	2008-12-08	2010-06-09	KRKA, tovarna zdravil, d.d., Novo mesto	A new process for the preparation of irbesartan
US20120046364A1 (en)	2009-02-10	2012-02-23	Metabasis Therapeutics, Inc.	Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US8486940B2 (en)	2009-09-11	2013-07-16	Probiodrug Ag	Inhibitors
HUP0900788A2 (en)	2009-12-16	2011-11-28	Sanofi Aventis	Process for producing 4-bromomethyl-biphenyl derivatives
EP2542549B1 (en)	2010-03-03	2016-05-11	Probiodrug AG	Inhibitors of glutaminyl cyclase
CA2789440C (en)	2010-03-10	2020-03-24	Probiodrug Ag	Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en)	2010-04-21	2013-09-24	Probiodrug Ag	Inhibitors
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
JP6050264B2 (ja)	2011-03-16	2016-12-21	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
BR112014014527A2 (pt)	2011-12-15	2017-06-13	Takeda Pharmaceuticals Usa Inc	combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
PL223830B1 (pl)	2012-04-03	2016-11-30	Univ Jagiellonski	Pochodne aromatycznych imidazolidynonów i ich zastosowanie
CA2905438A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
EP3004138B1 (en)	2013-06-05	2024-03-13	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase c, method of making and using same
ES2847904T3 (es)	2013-07-23	2021-08-04	Daiichi Sankyo Co Ltd	Medicamento para la prevención o el tratamiento de la hipertensión
JP6934859B2 (ja)	2016-03-24	2021-09-15	第一三共株式会社	腎疾患の治療のための医薬
KR20250007040A (ko)	2017-07-07	2025-01-13	베링거잉겔하임베트메디카게엠베하	고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
EP3461819B1 (en)	2017-09-29	2020-05-27	Probiodrug AG	Inhibitors of glutaminyl cyclase
US20240390332A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3340595A1 (de) *	1983-11-10	1985-05-23	Hoechst Ag, 6230 Frankfurt	Imidazolinone, verfahren zu ihrer herstellung und ihre verwendung im pflanzenschutz
DE3545597A1 (de) *	1985-12-21	1987-07-02	Celamerck Gmbh & Co Kg	Neue herbizid wirksame imidazolinone
CA1334092C (en) *	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
US4820843A (en) *	1987-05-22	1989-04-11	E. I. Du Pont De Nemours And Company	Tetrazole intermediates to antihypertensive compounds
EP0303863A3 (en) *	1987-08-17	1991-10-23	American Cyanamid Company	Benzenesulfonyl carboxamide compounds, intermediate compounds and methods of preparation thereof and use of said compounds and intermediate compounds as herbicidal agents
US5015651A (en) *	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) *	1988-01-07	1996-04-09	David John Carini	Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0407342A3 (en) *	1989-07-06	1991-07-10	Ciba-Geigy Ag	Pyrimidine derivatives
DE69024556T2 (de) *	1989-07-28	1996-10-17	Merck & Co Inc	Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
ATE113281T1 (de) *	1989-08-02	1994-11-15	Takeda Chemical Industries Ltd	Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
US5100897A (en) *	1989-08-28	1992-03-31	Merck & Co., Inc.	Substituted pyrimidinones as angiotensin ii antagonists
IL99372A0 (en) *	1990-09-10	1992-08-18	Ciba Geigy Ag	Azacyclic compounds

1991
- 1991-03-19 IE IE091391A patent/IE910913A1/en not_active IP Right Cessation
- 1991-03-19 TW TW080102155A patent/TW201738B/zh not_active IP Right Cessation
- 1991-03-19 PT PT97078A patent/PT97078B/pt not_active IP Right Cessation
- 1991-03-19 NZ NZ237476A patent/NZ237476A/en unknown
- 1991-03-20 AT AT91400745T patent/ATE167475T1/de active
- 1991-03-20 IL IL11082091A patent/IL110820A/en not_active IP Right Cessation
- 1991-03-20 HU HU603/91A patent/HU221188B1/hu unknown
- 1991-03-20 DE DE1999175029 patent/DE19975029I2/de active Active
- 1991-03-20 DK DK91400745T patent/DK0454511T3/da active
- 1991-03-20 PL PL91293015A patent/PL165945B1/pl unknown
- 1991-03-20 MY MYPI91000464A patent/MY115638A/en unknown
- 1991-03-20 SG SG1996005558A patent/SG49053A1/en unknown
- 1991-03-20 AU AU75610/91A patent/AU641005B2/en not_active Expired
- 1991-03-20 JP JP3506471A patent/JP2868313B2/ja not_active Expired - Lifetime
- 1991-03-20 WO PCT/FR1991/000224 patent/WO1991014679A1/fr active IP Right Grant
- 1991-03-20 KR KR1019910701647A patent/KR0175310B1/ko not_active IP Right Cessation
- 1991-03-20 DE DE69129606T patent/DE69129606T2/de not_active Expired - Lifetime
- 1991-03-20 CA CA002057913A patent/CA2057913C/en not_active Expired - Lifetime
- 1991-03-20 PL PL91304152A patent/PL166581B1/pl unknown
- 1991-03-20 SK SK1256-98A patent/SK283197B6/sk not_active IP Right Cessation
- 1991-03-20 PL PL91304153A patent/PL166403B1/pl unknown
- 1991-03-20 IL IL9761291A patent/IL97612A/en active Protection Beyond IP Right Term
- 1991-03-20 UA UA5010343A patent/UA42669A/uk unknown
- 1991-03-20 CZ CS1991745A patent/CZ287064B6/cs not_active IP Right Cessation
- 1991-03-20 EP EP91400745A patent/EP0454511B1/fr not_active Expired - Lifetime
- 1991-03-20 HU HU9302497A patent/HU223141B1/hu active IP Right Grant
- 1991-03-20 RU SU5010343/04A patent/RU2099331C1/ru active
- 1991-03-20 HU HU9302497A patent/HUT67648A/hu active IP Right Revival
- 1991-03-20 SK SK745-91A patent/SK280096B6/sk not_active IP Right Cessation
- 1991-03-20 ES ES91400745T patent/ES2119764T3/es not_active Expired - Lifetime
- 1991-11-19 FI FI915458A patent/FI103407B1/fi active Protection Beyond IP Right Term
- 1991-11-19 NO NO914528A patent/NO301977B1/no not_active IP Right Cessation
1992
- 1992-06-26 MX MX9203586A patent/MX9203586A/es active IP Right Grant
1993
- 1993-02-25 LV LVP-93-147A patent/LV10439B/en unknown
1994
- 1994-08-30 IL IL11082094A patent/IL110820A0/xx unknown
1996
- 1996-01-15 CZ CZ1996120A patent/CZ287225B6/cs not_active IP Right Cessation
1997
- 1997-12-10 JP JP9339895A patent/JPH10279566A/ja not_active Withdrawn
1998
- 1998-08-04 HK HK98109660A patent/HK1008918A1/xx not_active IP Right Cessation
- 1998-08-21 LU LU90279C patent/LU90279I2/fr unknown
- 1998-09-16 NO NO1998021C patent/NO1998021I1/no unknown
- 1998-12-02 NL NL980039C patent/NL980039I2/nl unknown
1999
- 1999-03-05 NL NL990006C patent/NL990006I2/nl unknown
- 1999-03-12 LU LU90371C patent/LU90371I2/xx unknown
- 1999-12-09 NO NO1999025C patent/NO1999025I1/no unknown

Also Published As

Publication number	Publication date
PL293015A1 (nl)	1993-02-08
PT97078A (pt)	1991-11-29
NO301977B1 (no)	1998-01-05
SK280096B6 (sk)	1999-08-06
KR920702349A (ko)	1992-09-03
CS74591A3 (en)	1991-11-12
ES2119764T3 (es)	1998-10-16
NZ237476A (en)	1994-01-26
SK283197B6 (sk)	2003-03-04
DK0454511T3 (da)	1999-04-06
CZ287064B6 (cs)	2000-08-16
HK1008918A1 (en)	1999-05-21
HU223141B1 (hu)	2004-03-29
EP0454511B1 (fr)	1998-06-17
IE910913A1 (en)	1991-09-25
NL990006I1 (nl)	1999-05-03
NO914528D0 (no)	1991-11-19
FI103407B (fi)	1999-06-30
HUT67648A (en)	1995-04-28
PL165945B1 (pl)	1995-03-31
DE69129606D1 (de)	1998-07-23
UA42669A (uk)	2001-11-15
ATE167475T1 (de)	1998-07-15
FI915458A0 (fi)	1991-11-19
HU9302497D0 (en)	1993-11-29
CA2057913A1 (en)	1991-09-21
IL110820A (en)	1995-11-27
HUT61284A (en)	1992-12-28
LV10439B (en)	1995-08-20
NO1998021I1 (no)	1998-10-05
IL97612A (en)	1995-08-31
IL110820A0 (en)	1994-11-11
LV10439A (lv)	1995-02-20
KR0175310B1 (ko)	1999-02-18
PL166403B1 (pl)	1995-05-31
NL980039I1 (nl)	1999-02-01
DE19975029I2 (de)	2002-05-08
JP2868313B2 (ja)	1999-03-10
EP0454511A1 (fr)	1991-10-30
AU7561091A (en)	1991-10-21
CZ287225B6 (cs)	2000-10-11
RU2099331C1 (ru)	1997-12-20
TW201738B (nl)	1993-03-11
WO1991014679A1 (fr)	1991-10-03
NO914528L (no)	1992-01-17
LU90371I2 (fr)	1999-05-12
JPH10279566A (ja)	1998-10-20
IL97612A0 (en)	1992-06-21
LU90279I2 (fr)	1998-10-21
MY115638A (en)	2003-08-30
SG49053A1 (en)	1998-05-18
FI103407B1 (fi)	1999-06-30
NL980039I2 (nl)	1999-09-01
PT97078B (pt)	1997-07-31
NO1999025I1 (no)	1999-12-09
AU641005B2 (en)	1993-09-09
MX9203586A (es)	1992-07-01
JPH04506222A (ja)	1992-10-29
DE69129606T2 (de)	1998-12-17
CA2057913C (en)	1997-07-08
PL166581B1 (pl)	1995-06-30
HU913603D0 (en)	1992-07-28
HU221188B1 (en)	2002-08-28

Publication	Publication Date	Title
NL980039I1 (nl)	1999-02-01	N-gesubstitueerde heterocyclische derivaten, de bereiding hiervan, farmaceutische preparaten die deze bevatten.
ATE204269T1 (de)	2001-09-15	Substituierte biphenyl- oder phenylpyridinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE69208089D1 (de)	1996-03-14	Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
CA2505033A1 (en)	2004-06-17	Non-nucleoside reverse transcriptase inhibitors
NO940737D0 (no)	1994-03-03	Antidepressive midler
DK78995A (da)	1995-07-05	Anvendelse af visse substituerede arylalkylaminer til fremstilling af et lægemiddel med neurobeskyttende virkning
TW333532B (en)	1998-06-11	Benzopyrans
DE69603309D1 (de)	1999-08-26	Tricyclische Amidverbindungen, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
BR9801448B1 (pt)	2009-01-13	compostos heterocÍclicos, processo para sua preparaÇço e composiÇÕes farmacÊuticas contendo os mesmos.
DE69403896D1 (de)	1997-07-24	4-amino-2-(hetero)aryl-butanamide verwenbar als 5-ht1a-antagonisten
AR011138A1 (es)	2000-08-02	Compuestos derivados de 4-aminoalcoxi-1,3-dihidrobenzomidazol-2-onas, composicion farmaceutica que los comprende y uso de los mismos para lafabricacion de un medicamento util, agonistas del autorreceptor de la dopamina.

Legal Events

Date	Code	Title	Description
2005-04-01	TC	Notification that names of proprietors of granted supplementary protection certificates were modified